Biotech RadarJobs updated

COMPANY

Rallybio

HQ: New Haven, CT source · rallybio.com ↗ · New England

Clinical Phase 2

Keywords: rare disease rare diseases Fetal and Neonatal Alloimmune Thrombocytopenia Hematologic Diseases Autoimmune Diseases Anti-(integrin beta-3) human monoclonal antibody RLYB116

Location: New Haven, CT · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants source ↗
  2. Trial start 2: Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization source ↗
  3. Trial start —: Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia source ↗

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT05345561Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune ThrombocytopeniaNot listedCompletedMar 14, 2022Jan 31, 2025 (actual)
NCT06435845Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization2TerminatedNov 21, 2024Oct 1, 2025 (actual)
NCT06797375Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy ParticipantsPhase 1CompletedApr 14, 2025Feb 9, 2026 (actual)
Feedback